Balzer-Geldsetzer, Monika
Ferreira, Joaquim
Odin, Per
Bloem, Bastiaan R.
Meissner, Wassilios G.
Lorenzl, Stefan
Wittenberg, Michael
Dodel, Richard
Schrag, Anette https://orcid.org/0000-0002-9872-6680
Funding for this research was provided by:
EU Joint Programme Neurodegenerative Disease Research (Economic and Social Research Council ES/L009250/1)
Article History
Received: 17 January 2018
Accepted: 18 October 2018
First Online: 5 November 2018
Ethics approval and consent to participate
: All study sites received approval of their local ethics committee before study start; all patients gave their written informed consent before study participation.The CLaSP study is being conducted in compliance with the Helsinki Declaration [], i.e. detailed oral and written information is given to the patients and their informant to ensure that the patient fully understands potential risks and benefits of the study. The study protocol was approved by the local ethics committees of all participating study sites (London:Camden and Islington NRES Committee 14/LO/0612, Bordeaux: South West and Overseas Protection Committee III (South West and Overseas Protection Committee). 2014-A01501–46, Lisbon:Centro Hospitalar Lisboa Norte, DIRCLN-19SET2014–275, Lund: EPN Regionala etikprovningsnamnden: Lund (EPN Regional Ethics Name: Lund). <i>JPND NC 559–002,</i> Marburg: Ethik-Kommission bei der Landesarztekammer Hessen (Ethics Commission at the State Medical Association Hesse). MC 309/2014, Munich: Ethikkommission bei der LMU Munchen (Ethics committee at the LMU Munchen). 193–14, Nijmegen: Radboud universitair medisch centrum, Concernstaf Kwaliteit en Veiligheid, Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen (Radboud university medical center,Group staff Quality and Safety Human Research Committee, Arnhem-Nijmegen region). DJ/CMO300).
: Participants (patients and their caregivers) are included in the study after giving their written informed consent. In case the patient lacks capacity to give consent to the study due to severe cognitive impairment, the decision on study participation is made by a legal guardian or consultee, depending on the ethical and legal requirements at each site. All participants (patients and caregivers) can withdraw from the study at any point in time without any negative implications.
: All authors have read the final manuscript and consented publication.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.